ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  alpelisib
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over, postmenopausal if female
Trial IDs: CBYL719C2301, NCI-2015-01171, 2015-000340-42, NCT02437318
Alpelisib, Cetuximab, and Cisplatin in Treating Patients with HPV-Associated Oropharyngeal Cancer That Can Be Removed by Surgery
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 14-057, NCI-2016-00439, NCT02298595
PI3K Inhibitor BYL719 and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER-2 Negative Stage III or IV Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719XUS06T, NCI-2015-00802, STUDY00001632, NCT02379247
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CBYL719X2402, NCI-2017-01082, NCT03056755
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, 2013-001219-57, NCT01872260
LJM716, Alpelisib, and Trastuzumab in Treating Patients with Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-057, NCI-2014-01362, NCT02167854
Sotrastaurin Acetate and Alpelisib in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAN4901, NCI-2015-00753, CAEB071AUS01T, NCT02273219
Cetuximab, BYL719, and Intensity-Modulated Radiation Therapy in Treating Patients with Stage III-IVB Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-116, NCI-2014-02290, NCT02282371
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLSZ102X2101, NCI-2016-00957, 2015-004016-38, NCT02734615
Start Over